Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
22.24 USD | +7.13% | +1.83% | -27.09% |
Apr. 15 | Intellia Therapeutics, Inc. Appoints Michael P. Dube as Principal Accounting Officer | CI |
Mar. 25 | Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-27.09% | 2B | |
+2.54% | 42.75B | |
+47.70% | 41.61B | |
+11.86% | 41.34B | |
-8.83% | 26.59B | |
+7.35% | 25.49B | |
-22.81% | 18.12B | |
+30.49% | 12.24B | |
-2.15% | 11.76B | |
+9.13% | 11B |
- Stock Market
- Equities
- NTLA Stock
- News Intellia Therapeutics, Inc.
- Canaccord Genuity Adjusts Price Target on Intellia Therapeutics to $73 From $72, Maintains Buy Rating